Table 2.
Mean (standard deviation) baselines prior to each randomised treatment for efficacy and systemic endpoints. There were no significant differences for any endpoints
| Aerodose® Inhaler | Pari LC Plus Nebulizer | Ventolin Evohaler | ||||
|---|---|---|---|---|---|---|
| Airway endpoints | ||||||
| FEV1 (L) | 1.87 (0.61) | 1.91 (0.70) | 1.85 (0.61) | |||
| FEF25–75 (L/ s) | 1.14 (0.46) | 1.17 (0.58) | 1.14 (0.53) | |||
| Systemic endpoints | ||||||
| K+ (mmol/l) | 3.98 (0.18) | 3.97 (0.30) | 3.89 (0.22) | |||
| T wave amplitude (mV) | 0.30 (0.20) | 0.33 (0.18) | 0.26 (0.14) | |||
| QTc Interval (ms) | 384.6 (24.5) | 385.5 (22.7) | 397.6 (20.6) | |||
| Heart Rate (bpm) | 70 (8.2) | 68 (10.3) | 71 (8.79) | |||
| Systolic BP (mmHg) | 129 (13.7) | 132 (19.0) | 132 (16.3) | |||
| Diastolic BP (mmHg) | 79 (7.4) | 78 (11.3) | 80 (12.4) | |||